AKT1 and cancer: In addition, various rapalogues, such as everolimus and temsirolimus, pan-PI3K inhibitors, dual inhibitors targeting PI3K and mTOR, as well as mTOR and AKT signaling, have yielded promising pre-clinical results within a variety of cancer models 40.